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T cells play a critical role in normal immune 
responses and in the pathogenesis of many 
 autoimmune diseases. T cells are normally acti-
vated by signals mediated by the antigen re-
ceptor and by costimulatory molecules, the best 
characterized of which is the CD28 surface 
receptor, which binds to CD80 and CD86 
 receptors on APCs (1). CD28 plays a critical 
role in the normal expression of Th1 and 
Th2 cytokines (2, 3), with CD28-defi cient 
cells demonstrating a profound defi ciency in 
expre ssion of multiple cytokines (4, 5). Th2 
cytokines have been shown to play a pivotal 
role in the pathogenesis of allergic diseases 
such as asthma (6). Cytokine-dependent sig-
naling pathways that mediate both Th1 and 
Th2 cytokine production are well character-
ized with Th2 diff erentiation controlled by 
IL-4, STAT6, and the downstream transcrip-
tion factors c-maf and GATA-3 (7–9). The 
pathways downstream of CD28 and other 
costimulatory molecules that are required for 
production of Th2 cytokines are, however, 
less well understood.
Previous work from our group has shown 
that the serine-threonine kinase Akt can cor-
rect the defi ciency in Th1 cytokine produc-
tion exhibited by CD28-defi cient T cells (5). 
Interestingly, however, Akt had no apparent 
eff ect on the production of Th2 cytokines. 
This result suggested the existence of an al-
ternative pathway downstream of CD28 that 
regulates Th2 cytokines. The activation of Akt 
is regulated by the upstream serine-threonine 
phosphoinositide-dependent kinase 1 (PDK1) 
(10). Recently, we have shown that expres-
sion of an activated form of PDK1, designated 
PDK1–kinase hyperactive (KH), partially cor-
rects the defi ciency of Th2 cytokine produc-
tion in CD28-defi cient cells (11). This isoform 
of PDK1 contains a point mutation in the ki-
nase domain (A277V) that results in a three-
fold increase in kinase activity (12). Two types 
of signaling motifs in the CD28 cytoplasmic 
tail have been defi ned as critical for Th2 cy-
tokine expression in primary CD4+ T cells 
(11). Tyrosine residues that undergo induc-
ible phosphorylation represent the fi rst such 
motif. Mutation of tyrosine residues 170 and 
188 in CD28 results in defective Th2 cytokine 
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induction (11). Of note, the Y170 residue has been previ-
ously shown to bind the p85 subunit of phosphatidylinositol 
3-kinase (PI3K) and Grb-2 (13–15). A proline-rich region in 
the CD28 tail (16) represents a second motif required for Th2 
cytokine expression (11), as well as a potential binding site 
for proteins containing SH3 domains. Although expression 
of PDK1-KH alone did not autonomously correct Th2 cy-
tokine defects in CD28-defi cient primary T cells, coexpres-
sion with CD28 constructs mutated in either of these motifs 
corrected their defect in Th2 cytokine production (11). Co-
expression of Akt was unable to similarly complement the 
CD28 mutant proteins and restore Th2 cytokine production. 
As such, these signaling motifs in the CD28 cytoplasmic tail 
may act to generate signals that synergize with PDK1 to pro-
mote Th2 cytokine expression in primary T cells. In addition 
to eff ects on Th2 cytokine expression, PDK1-KH was able 
to autonomously restore Th1 cytokine production in CD28-
defi cient cells in a similar fashion to membrane-targeted Akt 
(11). This result suggests that, in addition to playing a role 
in Th2 cytokine production, PDK1 acts upstream of Akt in 
Th1 cytokine signaling pathways.
PDK1 is a ubiquitously expressed 67-kD serine-threonine 
kinase containing an amino-teminal kinase domain and a car-
boxy-terminal PH domain (10). PDK1 plays an important 
role in T cell thymic development (17), but its role in periph-
eral T cell function is unknown. Although PDK1 was origi-
nally identifi ed for its ability to phosphorylate Akt on a critical 
functional residue (18), it has also been shown to activate sev-
eral other serine-threonine kinases, including PKC isozymes, 
p70S6K, RSK, SGK, and cAMP-dependent protein kinase A 
(PKA) (10, 19–22). Akt contains a PH domain that mediates 
PIP3 binding and consequently colocalization with PDK1 
(23). Other substrates, notably PKC, RSK, and p70S6K, con-
tain a so-called PDK-interacting fragment (PIF) that mediates 
interaction with and facilitates phosphorylation by PDK1 (19, 
24). Structural analysis has revealed the presence of a hydro-
phobic region within the PDK1 kinase domain termed the 
“PIF pocket” that mediates interaction with the PIF domain 
(25). Gene knockout and “knockin” studies of PDK1 have 
provided several new insights into its function. Mice with 
deletion of the PDK1 gene or with knockin mutations in the 
PH domain or the PIF pocket all die by embryonic day 9.5, 
reinforcing the essential role of the kinase (26–28).
We originally hypothesized a role for PDK1 in CD28 
signaling as a result of the defi ned role of its substrate Akt in 
costimulation-dependent Th1 cytokine activation. Elevation 
of intracellular cAMP levels and activation of PKA have pre-
viously been shown to positively impact Th2 diff erentiation 
and IL-4 production (29–32). The mechanisms whereby 
PKA modulates Th2 cytokine expression remain incom-
pletely characterized. Other studies have demonstrated that 
PDK1 phosphorylates PKA at a critical threonine residue in 
its kinase domain in vitro (21, 22). We had hypothesized that 
PDK1 may mediate a distinct Th2 signaling pathway by acti-
vating PKA and now present data supporting this hypothesis. 
We demonstrate that PDK1 directly targets the IL-4 pro-
moter in the antigen-dependent murine Th2 cell line 
D10.4G1 (D10) (29) and that PKA acts downstream of PDK1 
in this pathway, which targets the NFAT P1 element in the 
IL-4 promoter. We show that the essential threonine residue 
of PKA is inducibly phosphorylated after CD3/CD28 
 engagement. Using RNA interference (RNAi) technology, 
Figure 1. PDK1 but not Akt activates the IL-4 promoter. (A) PDK1-KH 
or a myristoylated membrane targeted form of Akt (Akt myr) was co-
transfected with an IL-4 −800 Luciferase transcriptional reporter in the 
D10 cell line. 16 h later, 105 cells were either left unstimulated or were 
treated with ionomycin (0.5 μM) and were assayed for luciferase activity 
6 h later. Luciferase data are shown relative to unstimulated IL-4 (or other 
reporter) luciferase activity (relative activity = 1) throughout the paper 
unless otherwise stated. A representative experiment is shown with all 
such experiments shown in this manuscript repeated at least three times. 
The mean result for each sample (performed in duplicate) is shown. West-
ern blot expression controls were performed using 106 remaining cells 
with transfected PDK1-KH and Akt-myr compared with endogenous pro-
tein with quantifi cation of fold-overexpression. (B) PDK1 kinase activity is 
required for IL-4 promoter activation. PDK1-KH and a PDK1-KH construct 
with a kinase-inactivating S241A mutation were coexpressed with IL-4 
Luciferase. Western blot expression controls are shown. (C) PDK1-DN 
(S241A) blocks CD3/CD28-mediated activation of the IL-4 promoter. Wild-
type PDK1 or PDK1-DN were coexpressed with the IL-4 Luciferase re-
porter. After 16 h, cells were stimulated with plate-coated anti–mouse 
CD3 antibody with soluble mouse anti-CD28 (1:500 in media) or were 
placed in a control plate (unstim). Protein expression controls are shown.
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PDK1 expression is shown to be required in D10 T cells for 
maximal basal and inducible phosphorylation of PKA, as well 
as for activation of the IL-4 NFAT P1 transcriptional ele-
ment. We also show that PDK1 and the PKA catalytic sub-
unit physically interact, and that these kinases colocalize at 
the immune synapse. These studies link PDK-1 and cAMP-
dependent PKA in a pathway targeting IL-4 expression.
RESULTS
PDK1 activates the IL-4 promoter in D10 T cells
As discussed in the Introduction, we have previously re-
ported studies defi ning a role for PDK1 in Th2 cytokine 
production in primary T cells. We have now studied the ef-
fects of PDK1 on IL-4 promoter activity in the D10 Th2 
cell line. We initially observed that transfection of PDK1-KH 
potently increased IL-4 promoter activity in D10 cells (Fig. 1 
A). Maximal IL-4 promoter activation required the presence 
of the calcium ionophore ionomycin to simulate calcium-de-
pendent signals emanating from the antigen receptor. In con-
trast, transfection of a membrane-targeted form of the PDK1 
substrate Akt (Akt-myr) had minimal eff ects on the IL-4 
promoter under these conditions. Western blot analysis of 
PDK1-KH and Akt-myr levels compared with endogenous 
proteins showed similar levels of overexpression for each 
protein. We next tested whether activation of IL-4 required 
PDK1 kinase activity by introducing a previously described 
inactivating mutation (S241A) (33) into the PDK1 kinase 
domain. Introduction of this mutation into the PDK1-KH 
protein substantially reduced activation of the IL-4 promoter 
with both proteins overexpressed at similar levels (Fig. 1 B). 
Wild-type PDK1 containing the S241A mutation acted as a 
dominant negative (DN) isoform of PDK1 (PDK1-DN) be-
cause it was capable of blocking CD3/CD28-mediated acti-
vation of the IL-4 promoter (Fig. 1 C). In contrast, wild-type 
PDK1 expressed at similar levels did not block CD3/CD28 
stimulation of IL-4 promoter activity. That PDK1-S241A 
was indeed acting as a specifi c DN isoform was confi rmed by 
demonstrating that expression of this protein could block Akt 
phosphorylation by endogenous PDK1 after CD3/CD28 
stimulation (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20051715/DC1). These results, together 
with our previous studies in primary CD28-defi cient T cells, 
suggest that PDK1 may play a role in regulating the transcrip-
tional activity of the IL-4 gene.
Figure 2. PDK1 targets the NFAT P1 site in the IL-4 promoter. 
(A) Schematic of the IL-4 promoter showing selected promoter elements 
and the sequence of the proximal promoter from −91 to −36. The ele-
ments studied in this analysis are highlighted with larger letters with 
mutated nucleotides circled. (B) PDK1-KH activation of IL-4 requires the 
NFAT P1 site. PDK1-KH was coexpressed with wild type or mutant IL-4 
promoter constructs. Transfected D10 cells were treated with ionomycin 
6 h before measurement of luciferase activity (except for samples labeled 
unstim). (C) PDK1-KH was coexpressed with multimerized 2X-reporter 
constructs for IL-4 NFAT P1, NFAT P1/AP-1, and NFAT P0. Cells were 
treated with ionomycin or left unstimulated as labeled and assayed for 
luciferase activity.
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PDK1 targets the NFAT P1 element in the IL-4 promoter
We next mapped the transcriptional element required for ac-
tivation of the IL-4 promoter by PDK1. The murine IL-4 
luciferase construct mediating responsiveness to PDK1 con-
tained 740 base pairs of promoter sequence upstream of the 
transcription start site (34). We constructed deletion mutants 
of the promoter and found that the region spanning −91 to 
−36 of the promoter was required for activation of IL-4 by 
PDK1 (unpublished data). As shown in Fig. 2 A, this area of 
the promoter contains binding sites for NFAT and AP-1 
transcription factor families (34, 35), as well as a binding 
site for the Th2-specifi c transcription factor c-maf (8), which 
have all been shown to be important for normal IL-4 regu-
lation. Subsequent mutation of the NFAT P1 site, but not 
the NFAT P0 site or the c-maf and AP-1 binding sites, com-
pletely ablated activation of the IL-4 promoter by PDK1-KH 
(Fig. 2 B). As both NFAT sites in this region have been 
shown to be important for maximal IL-4 promoter activity 
(36, 37), it was unclear whether the NFAT P1 site is a spe-
cifi c target of PDK1 action or whether mutation of the site 
simply renders the promoter completely unresponsive to any 
stimuli. We confi rmed that the NFAT P1 site is a target of 
PDK1 activation by creating reporter constructs with multimers 
of this site. Expression of PDK1-KH preferentially activated 
an NFAT P1 reporter construct, but did not signifi cantly 
 infl uence the activity of the IL-4 NFAT P0 reporter (Fig. 
2 C). Creation of an NFAT P1 reporter with the neighboring 
AP-1 site (P1/AP-1) conferred increased responsiveness to 
ionomycin and PDK1. The NFAT P1 site may serve as a 
composite transcriptional element with the adjacent AP-1 
Figure 3. (A) PDK1 colocalizes with Akt at the immune synapse. 
D10 cells were transfected with myc-tagged wild-type PDK1 and with 
an Akt-GFP fusion protein. Transfected cells were allowed to form con-
jugates with CH27 B cells in the presence or absence of antigen. Cells 
were subsequently fi xed and stained with an anti-myc Cy3-conjugated 
antibody and visualized using a Zeiss deconvolution microscope. Bar, 
5 μm. (B) Kinetics of recruitment of PDK1 to the immune synapse. PDK1-
GFP localization after conjugate formation between D10 T cells and con-
albumin-loaded CH27 APCs. Green fl uorescence (top), DIC (middle), and 
pseudo-colored images (bottom) were obtained every 20 s for 20 min 
with time-lapse fl uorescence microscopy. Images are representative of 
several conjugates. *, APCs. (C) IL-4 promoter activation is sensitive to 
the PI3K inhibitor LY2940002. Cells were transfected with the IL-4 lucif-
erase construct and either left unstimulated or stimulated with plate-
bound anti-CD3ε antibody and soluble anti-CD28 antibody in the 
presence of LY294002 (10 μM) or DMSO control. (D) A PDK1 PH mutant 
(L472/474E) does not localize to the immune synapse. A representative 
micrograph is shown (top) for the PDK1 PH mutant in a D10-CH27 
 conjugate in the presence of antigen. Bar, 5 μm. Blinded analysis of 
20 conjugates (in two separate experiments) using wild-type PDK1 or 
the PDK1 PH mutant was performed. The mean number of conjugates 
in which the respective PDK1 protein localizes predominantly to the 
immune synapse, partially to the synapse, or to other subcellular 
 locations is shown (bottom).
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site as has been described for the distal IL-2 NFAT element 
(38). As PDK1 can activate NFAT P1 constructs lacking an 
AP-1 binding site, it likely has direct eff ects on the function 
of NFAT transcription factors. Enhanced activation by PDK1 
of the composite P1/AP-1 reporter could be explained by 
distinct eff ects of PDK1 on AP-1 transcription factors or may 
simply refl ect the well-established synergy between NFAT 
and AP-1 factors in composite transcriptional elements.
PDK1 localizes to the immune synapse
We were interested in examining the cellular localization of 
PDK1 in T cells because our results implicated PDK1 in CD28 
signaling and IL-4 production. We again used the D10 cell 
line, which expresses a TCR specifi c for a conalbumin peptide 
in the context of the MHC class II Iak subtype (29). The CH27 
B cell line serves as an eff ective APC in this system. We exam-
ined localization of PDK1 coexpressed with an Akt-GFP fu-
sion protein. Akt has been recently shown to localize to the 
area at the T cell–APC interface, designated the immune syn-
apse (39). We found that PDK1 is present mainly in the cyto-
plasm in resting T cells (Fig. 3 A, left) but translocates to the 
immune synapse after engagement by the APC (Fig. 3 A, 
right). Localization of PDK1 to the synapse was antigen-de-
pendent and conjugates were not seen in the absence of conal-
bumin (Fig. 3 A, left). PDK-1 colocalized with Akt at the 
synapse in an antigen-dependent fashion (Fig. 3 A, right).
The kinetics of PDK1 localization to the immune synapse 
was examined using live cell imaging of a PDK1-GFP fusion 
protein. In the representative time course shown (Fig. 3 B), 
initial contact is noted between the transfected D10 T cell 
and the CH27 APC by the second panel at the 40-s time 
point. Defi nitive contact is established by the third panel at 
2 min, with some immediate enrichment of PDK1 at the im-
mune synapse. A large amount of PDK1 is also noted in the 
trailing edge (uropod) of the T cell, which has reproducibly 
been noted in cells transfected with moderate-to-high 
amounts of PDK1. Peak enrichment of PDK1 at the synapse, 
especially in the central portion, was seen at the 3-min, 20-s 
time point, <3 min after initial conjugate formation. In most 
conjugates observed, enrichment of PDK1 to the synapse was 
generally noted to peak within 4 min of T cell–APC contact. 
PDK1 localization at the synapse subsided in the conjugate 
shown 4–6 min after peak enrichment. Visualization of Akt 
synapse localization essentially exhibited similar kinetics to 
PDK1, though Akt was noted to have even more pronounced 
central synapse localization (unpublished data), as has been 
described by others (39).
We next examined the role of PI3K activity in IL-4 pro-
moter activation and the role of the PH domain in PDK1 lo-
calization to the synapse. IL-4 promoter activation by TCR 
in the presence of CD28 costimulation was sensitive to the 
PI3K inhibitor LY294002 in the D10 cell line (Fig. 3 C). 
Akt localization to the immune synapse has been shown to 
require a functional PH domain (39), albeit several lines of 
evidence discussed thus far suggest that Akt is not the PI3K-
dependent substrate mediating IL-4 activation. We demon-
strated that localization of PDK1 to the immune synapse is 
also PI3K dependent, as point mutations of critical residues in 
the PH domain (40) disrupted localization to the T cell–APC 
interface (Fig. 3 D). In other experiments, treatment of D10 
cells with LY294002 also blocked PDK1 localization to the 
immune synapse (unpublished data).
Activation of the IL-4 promoter element by PDK1 requires 
cAMP-dependent PKA function
Our original rationale for studying the role of PDK1 in Th2 
cytokine activation was its putative role in activation of cAMP-
dependent PKA. As noted previously, cAMP and PKA have 
been shown to exert a positive infl uence on Th2 cytokine 
expression in several studies (29, 32). Evidence that PKA par-
ticipates in PDK1-mediated activation of the IL-4 promoter 
was initially provided by the observation that the PKA inhibi-
tor H89 could ablate both PDK1 and TCR/CD28-mediated 
activation of the IL-4 promoter (Fig. 4, A and B). Blockade 
of TCR/CD28-mediated IL-4 activation by this relatively 
specifi c inhibitor is an important observation as it indicates 
the existence of a PKA-dependent pathway that cannot sim-
ply be attributed to kinase overexpression. We evaluated the 
eff ects of H89 on calcium fl ux and Ras activation in D10 
cells to rule out nonspecifi c eff ects of the inhibitor and, in-
deed, saw no appreciable eff ects of H89 on these parameters 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20051715/DC1). Activation of the IL-4 promoter by 
PDK1 was also sensitive to the calcineurin inhibitor FK506, 
providing further evidence that NFAT transcriptional path-
ways are being targeted by PDK1 (Fig. 4 B).
We next expressed the catalytic subunit of PKA and stud-
ied its eff ects on the IL-4 promoter in D10 cells. Unless stated 
otherwise, we used the isoform of the human PKA catalytic 
subunit (PKAc) β2 predominantly expressed in human im-
mune tissues (41) for our studies. Use of this isoform was ad-
vantageous as it could easily be distinguished from endogenous 
mouse catalytic subunits as the result of a diff erence in molec-
ular weight. We have subsequently been able to replicate 
many of the results discussed here using expression of a mouse 
PKAc α subunit (unpublished data). As was observed with 
PDK1, expression of PKAc in D10 cells exhibited robust acti-
vation of the IL-4 promoter, with this activation ablated by 
mutation (T245A) of the putative PDK1 phosphorylation site 
(Fig. 4 C). This threonine 245 residue is analogous to the 
 critical threonine 197 (T197) residue in the kinase domain of 
other PKAc isoforms (including PKAc α) (42). Although 
PKAc T245A generally achieved slightly lower expression 
levels than wild-type protein (Fig. 4 C), this subtle reduction 
clearly could not account for the dramatic reduction in IL-4 
activation. Even expressed at lower levels, the T245A mutant 
acts as a potent DN isoform (PKAc DN), completely blocking 
PDK1-KH–mediated activation of IL-4. In contrast, wild-
type PKAc augmented PDK1-mediated activation (Fig. 4 C). 
Of additional note, expression of wild-type PKAc activates 
the IL-4 promoter with identical specifi city to PDK1 for the 
NFAT P1 element (unpublished data). Expression of the 
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PDK1-DN isoform was able to block activation of IL-4 by 
PDK1-KH, but not by PKAc (Fig. 4 D). This result suggested 
that PKAc likely acts downstream of PDK1 in this pathway.
RNAi knockdown of PDK1
The classical mode of PKAc regulation is via dissociation 
from PKA regulatory subunits in response to stimuli that ele-
vate cAMP levels (43). PKAc also has been shown to un-
dergo regulation by cAMP-independent mechanisms, as it 
can be maintained in an inactive state via association with 
IκB proteins (44). We next investigated whether PDK1 reg-
ulates PKA via phosphorylation of its kinase domain as well 
as via physical interaction and colocalization at the immune 
synapse. RNAi-mediated knockdown of PDK1 expression 
was used to assess whether PDK1 is responsible for phos-
phorylation of the critical threonine site in the PKAc kinase 
domain in D10 T cells. The role of PDK1 in PKA activation 
has been somewhat unclear because biochemical analyses in-
dicate that PKA is a substrate for PDK1 (21, 22), but analysis 
of PDK1-defi cient embryonic stem cells reportedly reveals 
normal PKA activity (45). Genetic studies have, however, 
implicated ksg1, the PDK1 fi ssion yeast analogue, as an up-
stream activator of PKA (46). 2 d after expression of mouse 
PDK1-specifi c versus control pooled small interfering RNAs 
(siRNAs) in D10 cells, we observed a substantial reduction in 
endogenous PDK1 expression and an associated reduction in 
phosphorylation of the putative target threonine in endoge-
nous PKAc (Fig. 5 A). The major isoform detected in D10 
cells is likely the PKAc α subunit because an α subunit pep-
tide-specifi c antibody recognizes the protein (Fig. 5 A, third 
row). Total expression of PKAc α and a control gene, tubu-
lin, were relatively unaff ected by the knockdown of PDK1 
expression. We next examined the eff ect of PDK1 knock-
down on activation of the critical NFAT P1 element in the 
IL-4 promoter. Consistent with our earlier data, CD3/
CD28-mediated activation of this element is markedly re-
duced in cells with a PDK1 knockdown (Fig. 5 B). As further 
evidence that PDK1 can modulate PKA activity, we observed 
Figure 4. Activation of the IL-4 promoter by PDK1-KH is inhibited 
by the PKA inhibitor H89. (A) Activation of the IL-4 promoter by CD3/
CD28 is inhibited by the PKA inhibitor H89. D10 cells were transfected 
with IL-4 luciferase and were either unstimulated or stimulated with anti-
CD3 antibody or with anti-CD3/CD28 antibodies in the presence of H89 
(10 μM) or a DMSO control. (B) PDK1-KH was cotransfected with IL-4 
luciferase into cells that were subsequently stimulated with ionomycin in 
the presence of vehicle (DMSO), PKA inhibitor H89 (10 μM), or calcineurin 
inhibitor FK506 (200 ng/ml). (C) PKAc activates the IL-4 promoter with 
PKAc T245A defective in activation and capable of blocking PDK1-KH–
mediated IL-4 activation. PDK1-KH, PKAc β2, and the PKAc β2 T245A 
mutant were cotransfected with IL-4 luciferase alone or in combination 
as labeled, with all samples undergoing ionomycin stimulation. Luciferase 
results are expressed relative to IL-4 Luciferase + vector in the presence 
of ionomycin (relative activity = 1). Protein expression controls are shown. 
Transfected PKA is visualized in the second row (PKAc β2) via anti-myc 
immunoblotting, whereas endogenous PKA is visualized in the third row 
(PKAc α) using a PKA catalytic α-specifi c antibody. (D) 10 μg of PDK1-KH 
or PKAc encoding plasmid vector was expressed alone or with 10 or 20 
μg of PDK1-DN and IL-4 Luciferase. All samples were stimulated with 
ionomycin with results expressed relative to vector control + ionomycin 
(relative activity = 1).
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that PDK1-KH stimulates activity of a cAMP-responsive ele-
ment (CRE) luciferase plasmid and that activation was 
blocked by H89 (Fig. 5 C). Interestingly, PDK1-mediated 
activation of CRE luciferase activity is also partially sensitive 
to LY294002 (Fig. 5 C), suggesting that membrane or syn-
apse induced localization of PDK1 by PI3K may be required 
for PKA activation.
PDK1 interacts with PKAc and colocalizes with PKAc
at the immune synapse
We next sought to defi ne whether PDK1 and PKAc physi-
cally associate and also to characterize their relative localiza-
tion in T cells. We were able to coimmunoprecipitate a small 
portion of coexpressed PKAc with PDK1 from 1% NP-40 
lysates of D10 T cells (Fig. 6 A). Physical interaction between 
PDK1 and PKAc, as detected in a yeast two-hybrid assay, has 
been previously reported (24). Microscopic studies demon-
strated that PDK1 and a PKAc-GFP fusion protein colocalize 
in part at the immune synapse, albeit a signifi cant fraction of 
PKAc-GFP localizes to the cytoplasm (Fig. 6 B). The PKA-
GFP construct used contained the murine PKAc α subunit 
fused to GFP (47). We have also performed microscopic 
studies on the human PKAc β1 subunit and observed similar 
partial localization to the synapse (unpublished data).
Figure 5. (A) Knockdown of PDK1 expression using RNAi oligos in 
D10 cells resulted in decreased PKAc 𝛂 phosphorylation at threo-
nine 197 in the kinase domain. D10 cells were transfected with pooled 
mouse-PDK1–specifi c or control pooled RNAi oligos and a nonsignaling 
human CD16/CD7 fusion construct. On day 2, transfected cells were se-
lected using magnetic bead selection targeting human CD16. Lysates were 
prepared from 106 cells and resolved by SDS-PAGE followed by subse-
quent immunoblotting. (B) Knockdown of PDK1 expression blocks CD3/
CD28-mediated activation of an IL-4 NFAT P1 reporter. D10 cells were 
contransfected with an NFAT P1/AP-1 luciferase construct, a nonsignal-
ing human CD16/CD7 fusion construct, and either pooled mouse-PDK1–
specifi c or control pooled RNAi oligos. At day 2, transfected cells were 
purifi ed. 105 cells were aliquoted in triplicate on a 96-well plate either 
unstimulated or stimulated with plate-bound anti-CD3ε/soluble anti-
CD28 antibody. Results of a representative experiment are expressed as 
mean luciferase signal with error bars representing standard deviations 
from the mean. (C) PDK1-KH activates a CRE in a PKA-dependent manner. 
PDK1-KH or a control vector were cotransfected with a CRE Luciferase 
reporter in D10 cells. Luciferase activity was subsequently measured from 
cells treated with DMSO control, H89, or LY294002.
Figure 6. (A) PDK1 interacts with the PKA catalytic subunit. PKAc 
was expressed alone or in the presence of PDK1. NP-40 (1%) extracts were 
prepared from 25 × 106 transfected cells. Both proteins were tagged with 
a myc-epitope. PDK1 was immunoprecipitated with an antibody against 
the PDK1 carboxy-terminal region and was subsequently immunoblotted 
for transfected PDK1 and PKA using an anti-myc antibody. 10% of the 
amount of extract used for immunoprecipitation was immunoblotted as 
shown (right). (B) PDK1 and PKA partially colocalize at the immune synapse. 
D10 cells were transfected with myc-tagged PDK1 and with a PKAc-GFP 
construct. Cells were allowed to form conjugates with antigen-loaded 
CH27 cells 16 h later. Cells were fi xed and stained with a myc-Cy3 anti-
body, with microscopy performed as described previously. Bar, 5 μm.
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PKAc is inducibly phosphorylated at threonine 197
in T cells by PDK1
PDK1 has been shown to inducibly phosphorylate several 
downstream substrates in both PI3K-dependent and indepen-
dent pathways (28). In T cells, PDK1-mediated phosphory-
lation of Akt and PKC-θ after CD3/CD28 stimulation has 
been described previously (5, 48). We sought to determine 
whether PKA phosphorylation was induced after CD3/CD28 
stimulation. Although some degree of basal phosphorylation 
of the T197 residue of endogenous PKAc α was clearly seen 
in D10 cells, phosphorylation of the site was augmented at 
both 30 and 90 min after CD3 and CD28 stimulation (Fig. 
7, A and B). A similar up-regulation of phosphorylation 
was seen for the target PDK1 residues in Akt and PKC-θ. 
PDK1-mediated phosphorylation of PKA (3.5 fold at 90 
min after stimulation) was shown to be PI3K-dependent, 
as induction of phosphorylation was blocked by incubation 
with LY2940002 (Fig. 7, A and B). Induction of Akt phos-
phorylation by PDK1 was PI3K dependent, which was con-
sistent with existing models of Akt activation (Fig. 7 A) (28). 
Interestingly, although phosphorylation of some PKC family 
members has been shown to proceed by a PI3K-independent 
pathway, induction of PKCθ after CD3/CD28 stimulation 
was also blocked in part by the PI3K inhibitor. These results 
argue that PDK1 localization to the synapse is important for 
phosphorylation of PKA and PKCθ, and not just Akt. It also 
argues that PI3K-mediated localization of PDK1 to the im-
mune synapse may be critical for activation of multiple sub-
strates in T cells.
Induction of PKA T197 phosphorylation by CD3/CD28 
was signifi cantly diminished in cells with a PDK1 expression 
knockdown by siRNA (Fig. 7 C). As was expected, induc-
tion of Akt phosphorylation was similarly blocked, whereas 
phospho-Erk induction was less aff ected. This result verifi ed 
that PDK1 expression was essential for both basal and stimu-
lated phosphorylation of the PKA T197 residue.
D I S C U S S I O N 
We have previously reported that PDK1 can help correct the 
defect in IL-4 cytokine production seen in CD28-defi cient 
primary T cells. Because Akt was unable to achieve similar 
eff ects on IL-4 expression, it was hypothesized that PDK1 
Figure 7. (A) PKA T197 phosphorylation is induced by CD3/CD28 
stimulation of D10 T cells. 2 × 106 D10 cells were aliquoted into indi-
vidual wells on a 24-well plate either unstimulated or stimulated with 
plate-bound anti-CD3ε/soluble anti-CD28 for the indicated times, in the 
presence of DMSO or LY2940002 (10 μM). NP-40 extracts (106 cells) were 
loaded in each lane followed by serial immunoblotting. (B) Quantitation 
of PKA T197 phosphorylation. PKAc α T197 phosphorylation and total 
PKAc α signal were quantitated using Image J software. The phospho-
T197 signal was divided by total PKA with the baseline T197 index (t = 0 
min) expressed as 1.0 for both DMSO/LY2940002 samples. Phospho-
T197/total PKA index was calculated for three separate experiments with 
the graph showing mean result and error bars representing standard de-
viations. (C) Knockdown of PDK1 expression blocks CD3/CD28-mediated 
induction of PKA T197 phosphorylation. D10 cells were contransfected 
with the CD16/CD7 fusion construct and either pooled mouse-PDK1–
specifi c or control pooled RNAi oligos. At day 2, transfected cells were 
purifi ed with 106 cells from each sample aliquoted on a 24-well plate 
either unstimulated or stimulated with plate-bound anti-CD3ε/soluble 
anti-CD28 for 90 min. NP-40 extracts (106 cells) were loaded in each lane 
followed by serial immunoblotting.
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targets a diff erent substrate, resulting in IL-4 expression. We 
have presented studies of PDK1 in the Th2 cell line D10 that 
reveal molecular mechanisms whereby PDK1 can modulate 
IL-4 expression. We show that PDK1 activates the IL-4 pro-
moter via a specifi c NFAT element and that PDK1 localizes 
to the synapse in a PI3K-dependent fashion. We defi ne PKA 
as the downstream target of PDK1 action leading to IL-4 ex-
pression using several approaches and show that PDK1 is re-
quired for phosphorylation of PKA at a critical kinase domain 
threonine residue in D10 T cells. CD3/CD28 stimulation 
induces the PDK1-mediated phosphorylation of PKA, with 
PDK1 and PKA shown to physically interact and partially 
colocalize at the immune synapse.
Expression of the PDK1-KH molecule in D10 T cells 
was shown in this report to potently activate the IL-4 pro-
moter via the NFAT P1 element. One potential concern re-
garding this result is that the observed eff ects of PDK1 and 
PKA may relate to overexpression. We have therefore used 
DN isoforms of PDK1 and PKA as a complementary ap-
proach to block signaling pathways mediated by the T cell 
receptor and CD28. Both pharmacologic inhibitors of PKA 
and the DN PDK constructs block IL-4 promoter expression 
mediated by endogenous proteins. As highly specifi c inhibi-
tors of PDK1 are not presently available, RNAi experiments 
have, instead, helped validate a role for PDK1 in phosphory-
lation of PKAc in T cells, and in regulation of the critical 
NFAT P1 element in the IL-4 promoter. Although earlier 
studies in PDK1-defi cient ES cells indicated normal phos-
phorylation of the PKA kinase domain (45), our results sug-
gest that there may be cell type–specifi c diff erences in the 
regulation of PKA phosphorylation.
Activation of an NFAT transcriptional element by PDK1 
suggests that this kinase targets multiple signaling pathways in 
T cells. In separate studies, we have observed that PDK1 can 
activate NF-κB pathways, possibly via activation of Akt and 
PKC-θ (unpublished data). Another recent report confi rms 
that PDK1 targets PKC-θ in the activation of NF-κB (48). 
However, PDK1 has multiple other substrates and as such 
appears capable of regulating multiple transcriptional ele-
ments. NFAT transcription factors have been shown to be 
critical for IL-4 expression in gene knockout studies, with 
NFATc1 defi ned as a likely positive regulator of IL-4 but 
NFATc2 and NFATc3 identifi ed as negative regulatory fac-
tors (49–51). Future studies are needed to determine whether 
PDK1 modulates the occupancy of the NFAT P1 site by 
NFATc1, as might be predicted from the aforementioned 
data. It is also worth noting that one study reports that rel 
transcription factors exert a regulatory infl uence in the region 
of the NFAT P1 site, though whether PDK1 mediates these 
eff ects awaits further studies (52). Lastly, it will be important 
to determine whether PKA modulates IL-4 expression in 
Th2 cells via direct phosphorylation of NFAT factors, which 
is known to take place (53), or via other mechanisms.
Microscopic analysis of PDK1 cellular localization re-
vealed several interesting fi ndings. As has been observed for 
several critical signaling molecules, PDK1 localizes to the im-
mune synapse in an antigen-dependent fashion, within min-
utes of conjugate formation. Not surprisingly, colocalization 
of PDK1 with Akt at the synapse was dependent on PI3K. 
IL-4 promoter activation by TCR and CD28 stimulation 
was also PI3K dependent. Of relevance to the signaling path-
way described in this report, PDK1 and PKAc colocalize par-
tially at the immune synapse. It will be interesting to examine 
the relative cellular localization of PKA regulatory subunits 
and A-kinase anchoring proteins (AKAPs) in T cells. AKAPs 
have been shown to form the core of large signaling com-
plexes containing PKA subunits, PKC family members, and 
the PP2A phosphatase in other cell types (54). The role of 
AKAPs in signaling complexes in T cells is largely undefi ned 
as is their role in PDK1-mediated eff ects on PKA in T cells.
Several lines of evidence were used to establish PKAc as 
an in vivo regulatory target of PDK1. Activation of IL-4 by 
PDK1 and CD3/CD28 is exquisitely sensitive to PKA inhi-
bition by H89. Additionally, PDK1-mediated activation was 
blocked by PKA-DN. Common targeting of the NFAT P1 
element by both PDK1 and PKA added further support to 
their combined role in this pathway. In addition to micro-
scopic studies revealing colocalization at the immune syn-
apse, biochemical studies established physical association 
between PDK1 and PKAc.
Our data have confi rmed that the CD3/CD28-mediated 
induction of PKA phosphorylation and the IL-4 promoter, as 
well the localization of PDK1 to the synapse, require PI3K 
activity. Activation of PKAc and a cAMP-responsive reporter 
by PDK1 were similarly dependent on PI3K. The sensitivity 
to LY2940002 of PKAc phosphorylation at the PDK1 target 
residue (Fig. 7, A and B) strongly supports a model in which 
PKAc must colocalize to the synapse with PDK1 for activa-
tion. A direct role for PI3K in PKAc localization to the syn-
apse has not been demonstrated, though PI3K may indirectly 
infl uence PKAc localization if interaction with PDK1 plays 
a role in PKAc synapse localization. Although resolution of 
this specifi c issue awaits further investigation, our data clearly 
indicate that PDK1 and PI3K are required for activation of 
PKAc in a pathway targeting IL-4.
Several unsettled issues remain with regard to the func-
tion of PKA in T cell biology. It is not clear whether a physi-
ologic trigger for cAMP elevation is necessary to allow 
dissociation of PKAc subunits from regulatory subunits and 
AKAPs, thereby allowing interaction with PDK1. Some data 
indicate that TCR and CD28 modulate cAMP levels in 
some settings (55), though the question has not been 
 addressed adequately in primary undiff erentiated T cells or 
Th2 cells. Another Gs-coupled receptor may be a source of 
elevated intracellular cAMP levels. An additional question is 
whether PDK1 plays a direct role in promoting the release 
of the PKA catalytic subunit from regulatory subunits in a 
cAMP-independent manner. Of additional note, PKAc 
has previously been shown to be associated with and be 
maintained in an inactive state by IκB proteins, undergoing 
cAMP-independent release and activation on NF-kB activa-
tion (44). Given the evidence that PDK1 activates NF-kB 
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pathways (48), we are investigating whether PDK1 may also 
exert a regulatory infl uence on PKAc by promoting this 
cAMP-independent pathway.
Our studies in the D10 line clearly represent a diff erent 
cellular system than naive primary T cells where we previ-
ously described a role for PDK1 in IL-4 regulation. Our goal 
with these studies was to defi ne molecular targets of PDK1 
with a future aim of analyzing their role in primary T cells. 
The model shown in Fig. 8 depicts activation of IL-4 by 
PKA downstream of PDK1. We have not excluded the pos-
sibility that PDK1 may exert eff ects on IL-4 expression by 
targeting multiple kinases including PKA, and possibly PKC-
θ, which has previously been implicated in IL-4 regulation 
(56) and has been recently shown to be a target of PDK1 ac-
tion (48). Further studies are needed to delineate the interre-
lationship of these complex signaling pathways.
MATERIALS AND METHODS
Cells. A rapidly dividing variant of the D10 line was obtained from M. 
Krummel (University of California, San Francisco, CA). D10 and CH27 
cells were maintained in RPMI 1640 with 10% heat-inactivated fetal bovine 
serum, 2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 2-mercaptoethanol (50 μM), as well as human IL-2 (50 U/ml; PBL 
biomedical laboratories) for the D10 cell line. Cells were restimulated peri-
odically (every 4–6 wk) with mitomycin C–treated splenocytes from B10.
BR mice and chicken conalbumin at 100 mg/ml (Sigma Aldrich). CH27 B 
cells were maintained in RPMI 1640 with 5% heat-inactivated fetal bovine 
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin.
DNA constructs. Human PDK1 and PKA β catalytic subunit 2 were am-
plifi ed from Jurkat cDNA by PCR and cloned into the expression vector 
pCDEF, with a myc tag placed in frame at the 5′ end of the cDNA. pCDEF-
Akt and Akt-GFP plasmids have been described previously (5, 39). The IL-4 
–800 promoter plasmid has been described previously (34). Mutants of vari-
ous plasmids were generated using the QuikChange mutagenesis system 
(Stratagene). NFAT P1, P1/AP-1, and P0 plasmids were generated by clon-
ing annealed oligonucleotides containing 2X multimers of the relevant sites 
into the pGL3-Luciferase vector. The CRE luciferase vector (57) and the 
PKA-GFP plasmid have been described previously (47). L. Kane (University 
of Pittsburgh, Pittsburgh, PA), C. Vaisse (University of California at San 
Francisco, San Francisco, CA), and D. Chetkovich (Northwestern Univer-
sity, Chicago, IL) provided plasmids.
Antibodies. Antibodies were obtained from the following sources: anti-
PDK1 used for Western blotting (BD Transduction Laboratories), anti-
PDK1 for immunoprecipitations (Upstate Laboratories), anti-phospho PKA 
(Biosource International), pan-PKA (Upstate Laboratories), anti-myc (Cell 
Signaling), rabbit anti–hamster IgG (Sigma-Aldrich), anti-CD3ε 2C11 (BD 
Biosciences), anti-CD28 37.51 (murine ascites preparation), and anti–human 
CD16-FITC (BD Biosciences).
Transfection/stimulations. D10 cells were resuspended at 35–50 × 106 
cells/ml and were electroporated with relevant plasmids in a Gene-Pulser 
(Bio-Rad Laboratories) at 250V, 950 μF. 20 μg of each plasmid was trans-
fected in such experiments (unless otherwise noted). Cells were cultured in 
10 ml complete D10 medium and IL-2 at 50 U/ml overnight, before subse-
quent luciferase assays, biochemical analyses, or microscopy.
Luciferase assays. Cells were resuspended at 2 × 106 cells/ml in complete 
D10 medium without IL-2. 50 μl of cells was aliquoted into round bottom 
96-well plates with 50 μl of media containing the relevant stimulus. Ionomy-
cin, H89, and LY294002 were purchased from CalBiochem. FK506 was ob-
tained from the UCSF pharmacy. For plate-coated CD3 stimulation, 96-well 
plates were coated overnight at 4°C with goat anti–hamster IgG (10 μg/ml 
in 0.1 M Carbonate Buff er), with subsequent washing and incubation with 
anti-CD3 antibody (1 μg/ml in medium) at 37°C for 2 h. Wells were washed 
once with complete D10 medium before addition of cells. Anti–mouse 
CD28 antibody was added where indicated (1:500 in media). After 6 h, 100 μl 
of cells was permeabilized with 11 μl luciferase harvest buff er (10% Triton 
X-100, 1 mM DTT and 0.2 M KPO4, pH 7.8) and incubated for 5 min at 
room temperature. Samples were transferred to an opaque 96-well plate and 
100 μl of luciferase assay buff er was added (10 mM ATP, 20 mM MgCl2, and 
0.2 M KPO4, pH 7.8). Luciferase activity was determined with a 10-s read-
ing after injection with 50 μl of 1 mM luciferin, in either a MicroLumat lu-
minometer or a Mithras LB 940 luminometer (EG&G Berthold).
Cell extract preparation/immunoprecipitations/SDS PAGE. Cells 
were washed in PBS and lysed on ice in 1% NP-40 buff er with 150 mM 
NaCl, 20 mM Tris pH 7.5 with protease inhibitors. After 20 min on ice, 
samples were centrifuged for 5 min at 13,000 revolutions/min in a Sorvall 
Biofuge Fresco at 4°C with postnuclear supernatants saved. Extracts were 
mixed with reducing sample buff er and boiled for 5 min before loading on 
a SDS polyacrylamide gel (10% unless stated otherwise). For immunopre-
cipitations, cell extracts were incubated with rotation for 4 h at 4°C with 
the precipitating antibody and 20 ml of protein G–sepharose bead slurry. 
Beads were subsequently centrifuged for 5 s before each of four washes 
with 1% NP-40 lysis buff er. Beads were resuspended in reducing buf-
fer and boiled for 5 min before loading on a gel. Ras activation assays are 
described in the supplemental Materials and methods section (available at 
http://www.jem.org/cgi/content/full/jem.20051715/DC1).
Immunoblotting. After resolution of proteins on an SDS-polyacrylamide 
gel, proteins were transferred to a PVDF membrane (Millipore) with a 
semidry blotting apparatus. Membranes were blocked in 3% BSA in 250 mM 
NaCl, 20 mM Tris, pH 7.5, 0.05% Tween 20 (TBS-T). Primary antibody 
was incubated in TBS-T, 1% BSA at a 1:1,000 dilution (unless stated other-
wise) either overnight at 4°C, or for 1 h at room temperature. Blots were 
washed four times for 5 min in TBS-T before incubation with the relevant 
secondary antibody-horseradish peroxidase (HRP) conjugate at 1:10,000 for 
30 min at room temperature. After four 10-min washes in TBS-T, mem-
branes were developed with enhanced chemiluminescence (GE Healthcare) 
and subsequent autoradiography. Blots were stripped with 67 mM Tris pH 
6.8, 2% SDS, 0.1% 2-mercaptoethanol before incubation with other anti-
bodies. Individual protein bands were quantifi ed following autoradiography 
with Image J 1.33u software (freeware; National Institutes of Health).
Immunocytostaining/microscopy. Cells were incubated overnight after 
transfection and live cells were isolated on a lympholyte (Cedarlane Laboratories) 
Figure 8. Model for activation of the IL-4 promoter by PDK1 and 
PKA in Th2 cells.
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gradient. CH27 cells were incubated overnight in complete CH27 medium 
with chicken conalbumin protein (100 μg/ml). Equal numbers of D10 and 
CH27 cells (4 × 106 cells total in 1 ml media) were mixed and centrifuged at 
1,200 g for 1 min with subsequent incubation at 37°C for 20 min. Medium 
was aspirated followed by gentle resuspension of conjugates in PBS, 1% BSA. 
105 cells were spotted on poly-L-lysine–coated slides followed by fi xation of 
cells in 4% formaldehyde for 20 min, one wash with PBS 0.2% BSA, and per-
meabilization with 0.2% Triton X-100. Cells were blocked for 10 min with 
PBS, 1% BSA, 2% normal mouse serum. Cells were stained with anti-myc 
Cy3 at 1:50 in blocking buff er. Cells were washed three times for 5 min and 
mounted with coverslips with polyvinyl alcohol mounting medium.
Images were collected on a Marianis system with a Sensicam cooled 
CCD camera (Cooke) attached to an Axiovert microscope with a Zeiss 
Plan-Apochromat 63X/1.4 NA oil objective (Carl Zeiss MicroImaging, 
Inc.). 15–20 fl uorescence and diff erential interference contrast (DIC) images 
were collected per stack. Data stacks (z-axis) were subjected to constrained 
iterative deconvolution using an Apple Macintosh G5 computer equipped 
with Slidebook software (Intelligent Imaging Innovations). Blinded analysis 
of PDK1 localization was performed by identifying conjugates with Akt lo-
calized at the immune synapse and by subsequent scoring of PDK1 localiza-
tion either as exclusively at the synapse, partially at the synapse, or completely 
excluded from the synapse.
For time lapse fl uorescence microscopy, we used a modifi ed Axiovert 
200M microscope with a Plan Neofl uar 40 objective (Carl Zeiss MicroImaging, 
Inc.). The microscope was fi tted with dual excitation and emission fi lter wheels 
and a Photometrics Coolsnap-HQ camera. Metamorph was the imaging and 
control software (Universal Imaging). Antigen-loaded CH27 cells were plated 
into coverslip wells (Nunc) and were maintained at 37°C on the heated stage of 
the microscope. PDK1-GFP transfected D10 cells were added into APC-
 containing coverslip wells. Data were collected for 20 min with 40-s intervals for 
DIC and green fl uorescence images at the midcell z-section. Time point  before 
the initial contact was observed between T cell and APC was set to “0.”
RNAi experiments. D10 cells were electroporated with mouse PDK1-
specifi c pooled siRNAs or control pooled siRNAs (250 nM fi nal concentra-
tion; Dharmacon). 44 h after transfection, live cells were isolated via 
centrifugation in a lympholyte gradient and were stained with anti–human 
CD16-FITC. Cells were analyzed by FACS to verify equivalent transfection 
effi  ciencies between samples. The remainder of cells were purifi ed using the 
MACS magnetic bead cell isolation system using anti-FITC conjugated 
beads (Miltenyi Biotec). 2 X 105 cells were analyzed by FACS to ensure en-
richment of transfected cells to >90% of total. 106 cells were resolved by 
SDS-PAGE and subjected to serial immunoblotting with several antibodies.
Online supplemental material. Fig. S1 demonstrates that the PDK1 
S241A mutant acts as a DN isoform and can block induction of Akt phos-
phorylation after CD3/CD28 stimulation of D10 T cells. Fig. S2 evalu-
ates the specifi city of the H89 inhibitor, demonstrating no appreciable 
eff ects on calcium fl ux and Ras activation in D10 cells. Figs. S1 and S2 
as well as a supplemental Materials and Methods section are available at 
http://www.jem.org/cgi/content/full/jem.20051715/DC1.
We thank M. Krummel and J. Jacobelli for advice and reagents. We thank members 
of the Weiss laboratory for helpful comments.
This work was supported by the Sandler Asthma Basic Research Center (to A. 
Nirula, M. Ho), the Abbott Scholar Award in Rheumatology Research (to A. Nirula), 
and the Rosalind Russell Medical Research Center for Arthritis.
The authors report no confl icting fi nancial interests.
Submitted: 24 August 2005
Accepted: 24 May 2006
R E F E R E N C E S 
 1. Salomon, B., and J.A. Bluestone. 2001. Complexities of CD28/B7: 
CTLA-4 costimulatory pathways in autoimmunity and transplantation. 
Annu. Rev. Immunol. 19:225–252.
 2. Fraser, J.D., B.A. Irving, G.R. Crabtree, and A. Weiss. 1991. Regulation 
of interleukin-2 gene enhancer activity by the T cell accessory molecule 
CD28. Science. 251:313–316.
 3. Rulifson, I.C., A.I. Sperling, P.E. Fields, F.W. Fitch, and J.A. Bluestone. 
1997. CD28 costimulation promotes the production of Th2 cytokines. 
J. Immunol. 158:658–665.
 4. Shahinian, A., K. Pfeff er, K.P. Lee, T.M. Kundig, K. Kishihara, A. 
Wakeham, K. Kawai, P.S. Ohashi, C.B. Thompson, and T.W. Mak. 
1993. Diff erential T cell costimulatory requirements in CD28-defi cient 
mice. Science. 261:609–612.
 5. Kane, L.P., P.G. Andres, K.C. Howland, A.K. Abbas, and A. Weiss. 
2001. Akt provides the CD28 costimulatory signal for up-regulation of 
IL-2 and IFN-γ but not TH2 cytokines. Nat. Immunol. 2:37–44.
 6. Shirai, T., K. Suzuki, N. Inui, T. Suda, K. Chida, and H. Nakamura. 
2003. Th1/Th2 profi le in peripheral blood in atopic cough and atopic 
asthma. Clin. Exp. Allergy. 33:84–89.
 7. O’Garra, A., and N. Arai. 2000. The molecular basis of T helper 1 and 
T helper 2 cell diff erentiation. Trends Cell Biol. 10:542–550.
 8. Ho, I.C., M.R. Hodge, J.W. Rooney, and L.H. Glimcher. 1996. The 
proto-oncogene c-maf is responsible for tissue-specifi c expression of in-
terleukin-4. Cell. 85:973–983.
 9. Zheng, W., and R.A. Flavell. 1997. The transcription factor GATA-3 
is necessary and suffi  cient for Th2 cytokine gene expression in CD4 T 
cells. Cell. 89:587–596.
10. Toker, A., and A.C. Newton. 2000. Cellular signaling: pivoting around 
PDK-1. Cell. 103:185–188.
11. Andres, P.G., K.C. Howland, A. Nirula, L.P. Kane, L. Barron, D. 
Dresnek, A. Sadra, J. Imboden, A. Weiss, and A.K. Abbas. 2004. 
Distinct regions in the CD28 cytoplasmic domain are required for T 
helper type 2 diff erentiation. Nat. Immunol. 5:435–442.
12. Paradis, S., M. Ailion, A. Toker, J.H. Thomas, and G. Ruvkun. 1999. 
A PDK1 homolog is necessary and suffi  cient to transduce AGE-1 PI3 
kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 
13:1438–1452.
13. Cai, Y.C., D. Cefai, H. Schneider, M. Raab, N. Nabavi, and C.E. 
Rudd. 1995. Selective CD28pYMNM mutations implicate phosphati-
dylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity. 
3:417–426.
14. Truitt, K.E., C.M. Hicks, and J.B. Imboden. 1994. Stimulation of 
CD28 triggers an association between CD28 and phosphatidylinositol 
3-kinase in Jurkat T cells. J. Exp. Med. 179:1071–1076.
15. Stein, P.H., J.D. Fraser, and A. Weiss. 1994. The cytoplasmic domain of 
CD28 is both necessary and suffi  cient for costimulation of interleukin-2 
secretion and association with phosphatidylinositol 3′-kinase. Mol. Cell. 
Biol. 14:3392–3402.
16. Holdorf, A.D., J.M. Green, S.D. Levin, M.F. Denny, D.B. Straus, V. 
Link, P.S. Changelian, P.M. Allen, and A.S. Shaw. 1999. Proline resi-
dues in CD28 and the Src homology (SH)3 domain of Lck are required 
for T cell costimulation. J. Exp. Med. 190:375–384.
17. Hinton, H.J., D.R. Alessi, and D.A. Cantrell. 2004. The serine kinase 
phosphoinositide-dependent kinase 1 (PDK1) regulates T cell develop-
ment. Nat. Immunol. 5:539–545.
18. Stokoe, D., L.R. Stephens, T. Copeland, P.R. Gaff ney, C.B. Reese, 
G.F. Painter, A.B. Holmes, F. McCormick, and P.T. Hawkins. 1997. 
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation 
of protein kinase B. Science. 277:567–570.
19. Biondi, R.M., A. Kieloch, R.A. Currie, M. Deak, and D.R. Alessi. 
2001. The PIF-binding pocket in PDK1 is essential for activation of 
S6K and SGK, but not PKB. EMBO J. 20:4380–4390.
20. Le Good, J.A., W.H. Ziegler, D.B. Parekh, D.R. Alessi, P. Cohen, 
and P.J. Parker. 1998. Protein kinase C isotypes controlled by phos-
phoinositide 3-kinase through the protein kinase PDK1. Science. 
281:2042–2045.
21. Cheng, X., Y. Ma, M. Moore, B.A. Hemmings, and S.S. Taylor. 1998. 
Phosphorylation and activation of cAMP-dependent protein kinase by 
phosphoinositide-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 
95:9849–9854.
22. Moore, M.J., J.R. Kanter, K.C. Jones, and S.S. Taylor. 2002. 
Phosphorylation of the catalytic subunit of protein kinase A. 
1744 PDK1 AND PKA REGULATE IL-4 ACTIVATION | Nirula et al.
Autophosphorylation versus phosphorylation by phosphoinositide-de-
pendent kinase-1. J. Biol. Chem. 277:47878–47884.
23. Anderson, K.E., J. Coadwell, L.R. Stephens, and P.T. Hawkins. 1998. 
Translocation of PDK-1 to the plasma membrane is important in allow-
ing PDK-1 to activate protein kinase B. Curr. Biol. 8:684–691.
24. Biondi, R.M., P.C. Cheung, A. Casamayor, M. Deak, R.A. Currie, 
and D.R. Alessi. 2000. Identifi cation of a pocket in the PDK1 kinase 
domain that interacts with PIF and the C-terminal residues of PKA. 
EMBO J. 19:979–988.
25. Biondi, R.M., D. Komander, C.C. Thomas, J.M. Lizcano, M. Deak, 
D.R. Alessi, and D.M. van Aalten. 2002. High resolution crystal struc-
ture of the human PDK1 catalytic domain defi nes the regulatory phos-
phopeptide docking site. EMBO J. 21:4219–4228.
26. Lawlor, M.A., A. Mora, P.R. Ashby, M.R. Williams, V. Murray-Tait, 
L. Malone, A.R. Prescott, J.M. Lucocq, and D.R. Alessi. 2002. Essential 
role of PDK1 in regulating cell size and development in mice. EMBO J. 
21:3728–3738.
27. Collins, B.J., M. Deak, J.S. Arthur, L.J. Armit, and D.R. Alessi. 2003. In 
vivo role of the PIF-binding docking site of PDK1 defi ned by knock-in 
mutation. EMBO J. 22:4202–4211.
28. McManus, E.J., B.J. Collins, P.R. Ashby, A.R. Prescott, V. Murray-
Tait, L.J. Armit, J.S. Arthur, and D.R. Alessi. 2004. The in vivo role 
of PtdIns(3,4,5)P(3) binding to PDK1 PH domain defi ned by knockin 
mutation. EMBO J. 23:2071–2082.
29. Schmidt, J., A. Hatzelmann, S. Fleissner, I. Heimann-Weitschat, R. 
Lindstaedt, and I. Szelenyi. 1995. Eff ect of phosphodiesterase inhibition 
on IL-4 and IL-5 production of the murine TH2-type T cell clone D10.
G4.1. Immunopharmacology. 30:191–198.
30. Lee, H.J., N. Koyano-Nakagawa, Y. Naito, J. Nishida, N. Arai, 
K. Arai, and T. Yokota. 1993. cAMP activates the IL-5 promoter 
 synergistically with phorbol ester through the signaling pathway 
 involving protein kinase A in mouse thymoma line EL-4. J. Immunol. 
151:6135–6142.
31. Novak, T.J., and E.V. Rothenberg. 1990. cAMP inhibits induction of 
interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. 
USA. 87:9353–9357.
32. Tokoyoda, K., K. Tsujikawa, H. Matsushita, Y. Ono, T. Hayashi, Y. 
Harada, R. Abe, M. Kubo, and H. Yamamoto. 2004. Up-regulation 
of IL-4 production by the activated cAMP/cAMP-dependent protein 
kinase (protein kinase A) pathway in CD3/CD28-stimulated naive T 
cells. Int. Immunol. 16:643–653.
33. Casamayor, A., N.A. Morrice, and D.R. Alessi. 1999. Phosphorylation 
of Ser-241 is essential for the activity of 3-phosphoinositide-dependent 
protein kinase-1: identifi cation of fi ve sites of phosphorylation in vivo. 
Biochem. J. 342:287–292.
34. Szabo, S.J., J.S. Gold, T.L. Murphy, and K.M. Murphy. 1993. 
Identifi cation of cis-acting regulatory elements controlling interleukin-
4 gene expression in T cells: roles for NF-Y and NF-ATc. Mol. Cell. 
Biol. 13:4793–4805.
35. Todd, M.D., M.J. Grusby, J.A. Lederer, E. Lacy, A.H. Lichtman, and 
L.H. Glimcher. 1993. Transcription of the interleukin 4 gene is regu-
lated by multiple promoter elements. J. Exp. Med. 177:1663–1674.
36. Bruhn, K.W., K. Nelms, J.L. Boulay, W.E. Paul, and M.J. Lenardo. 
1993. Molecular dissection of the mouse interleukin-4 promoter. Proc. 
Natl. Acad. Sci. USA. 90:9707–9711.
37. Li-Weber, M., P. Salgame, C. Hu, I.V. Davydov, O. Laur, S. Klevenz, 
and P.H. Krammer. 1998. Th2-specifi c protein/DNA interactions at 
the proximal nuclear factor-AT site contribute to the functional activity 
of the human IL-4 promoter. J. Immunol. 161:1380–1389.
38. Jain, J., P.G. McCaff rey, Z. Miner, T.K. Kerppola, J.N. Lambert, G.L. 
Verdine, T. Curran, and A. Rao. 1993. The T-cell transcription factor 
NFATp is a substrate for calcineurin and interacts with Fos and Jun. 
Nature. 365:352–355.
39. Kane, L.P., M.N. Mollenauer, and A. Weiss. 2004. A proline-rich motif 
in the C terminus of Akt contributes to its localization in the immuno-
logical synapse. J. Immunol. 172:5441–5449.
40. Komander, D., A. Fairservice, M. Deak, G.S. Kular, A.R. Prescott, C. 
Peter Downes, S.T. Safrany, D.R. Alessi, and D.M. van Aalten. 2004. 
Structural insights into the regulation of PDK1 by phosphoinositides 
and inositol phosphates. EMBO J. 23:3918–3928.
41. Orstavik, S., N. Reinton, E. Frengen, B.T. Langeland, T. Jahnsen, and 
B.S. Skalhegg. 2001. Identifi cation of novel splice variants of the hu-
man catalytic subunit Cbeta of cAMP-dependent protein kinase. Eur. J. 
Biochem. 268:5066–5073.
42. Cauthron, R.D., K.B. Carter, S. Liauw, and R.A. Steinberg. 1998. 
Physiological phosphorylation of protein kinase A at Thr-197 is by a 
protein kinase A kinase. Mol. Cell. Biol. 18:1416–1423.
43. Griffi  oen, G., and J.M. Thevelein. 2002. Molecular mechanisms con-
trolling the localisation of protein kinase A. Curr. Genet. 41:199–207.
44. Zhong, H., H. SuYang, H. Erdjument-Bromage, P. Tempst, and S. 
Ghosh. 1997. The transcriptional activity of NF-κB is regulated by 
the IκB-associated PKAc subunit through a cyclic AMP-independent 
mechanism. Cell. 89:413–424.
45. Williams, M.R., J.S. Arthur, A. Balendran, J. van der Kaay, V. Poli, P. 
Cohen, and D.R. Alessi. 2000. The role of 3-phosphoinositide-depen-
dent protein kinase 1 in activating AGC kinases defi ned in embryonic 
stem cells. Curr. Biol. 10:439–448.
46. Tang, Y., and M. McLeod. 2004. In vivo activation of protein kinase A 
in Schizosaccharomyces pombe requires threonine phosphorylation at its 
activation loop and is dependent on PDK1. Genetics. 168:1843–1853.
47. Chetkovich, D.M., L. Chen, T.J. Stocker, R.A. Nicoll, and D.S. 
Bredt. 2002. Phosphorylation of the postsynaptic density-95 (PSD-95)/
discs large/zona occludens-1 binding site of stargazin regulates bind-
ing to PSD-95 and synaptic targeting of AMPA receptors. J. Neurosci. 
22:5791–5796.
48. Lee, K.Y., F. D’Acquisto, M.S. Hayden, J.H. Shim, and S. Ghosh. 
2005. PDK1 nucleates T cell receptor-induced signaling complex for 
NF-κB activation. Science. 308:114–118.
49. Ranger, A.M., M.R. Hodge, E.M. Gravallese, M. Oukka, L. Davidson, 
F.W. Alt, F.C. de la Brousse, T. Hoey, M. Grusby, and L.H. Glimcher. 
1998. Delayed lymphoid repopulation with defects in IL-4-driven re-
sponses produced by inactivation of NF-ATc. Immunity. 8:125–134.
50. Rengarajan, J., B. Tang, and L.H. Glimcher. 2002. NFATc2 and 
NFATc3 regulate T(H)2 diff erentiation and modulate TCR-respon-
siveness of naive T(H)cells. Nat. Immunol. 3:48–54.
51. Brogdon, J.L., D. Leitenberg, and K. Bottomly. 2002. The potency of 
TCR signaling diff erentially regulates NFATc/p activity and early IL-4 
transcription in naive CD4+ T cells. J. Immunol. 168:3825–3832.
52. Li-Weber, M., M. Giasi, and P.H. Krammer. 1998. Involvement of Jun 
and Rel proteins in up-regulation of interleukin-4 gene activity by the 
T cell accessory molecule CD28. J. Biol. Chem. 273:32460–32466.
53. Chow, C.W., and R.J. Davis. 2000. Integration of calcium and cyclic 
AMP signaling pathways by 14-3-3. Mol. Cell. Biol. 20:702–712.
54. Diviani, D., and J.D. Scott. 2001. AKAP signaling complexes at the 
cytoskeleton. J. Cell Sci. 114:1431–1437.
55. Abrahamsen, H., G. Baillie, J. Ngai, T. Vang, K. Nika, A. Ruppelt, T. 
Mustelin, M. Zaccolo, M. Houslay, and K. Tasken. 2004. TCR- and 
CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts poten-
tiates TCR signaling. J. Immunol. 173:4847–4858.
56. Hehner, S.P., M. Li-Weber, M. Giaisi, W. Droge, P.H. Krammer, and 
M.L. Schmitz. 2000. Vav synergizes with protein kinase Cθ to mediate 
IL-4 gene expression in response to CD28 costimulation in T cells. J. 
Immunol. 164:3829–3836.
57. Spengler, D., C. Waeber, C. Pantaloni, F. Holsboer, J. Bockaert, P.H. 
Seeburg, and L. Journot. 1993. Diff erential signal transduction by fi ve 
splice variants of the PACAP receptor. Nature. 365:170–175. 
